太盟成为陕西必康制药有限公司最大投资人，支持其收购制药企业，及建设新的医药研发和生产基地
北京时间 2 月 27 日 陕西必康制药有限公司（下称必康制药）宣布，太盟投资集团（ PAG ）已于日前完成对必康制药控股有限公司（下称必康控股）总计 2.5 亿美元（约 16 亿人民币）的投资，从而成为必康制药最大投资人。与此同时，必康控股、其全资控股的香港必康国际有限公司（下称必康国际）以及必康制药改组了董事会。新一届董事会阵容豪华，全部由资深专业人员组成。其中，太盟投资集团主席兼首席执行官单伟建出任董事长，董事会的其他成员包括代表各投资方的红杉资本、中国光大控股、美国 SIG 以及太盟投资集团的高级专业人员，必康制药的高管在八个席位中占三席，分别由必康制药的创始人李宗松、执行总裁香兴福和财务总监王成杰担任。
单伟建表示，“太盟将以自己的资源、能力和丰富的经验全力支持必康的发展，通过新的董事会，我们将进一步提升必康的公司法人治理和专业管理的水平，使其达到国际一流的标准。”红杉资本与光大控股也表示将继续一如既往的按照公司内涵式稳步发展与外延式并购整合并举的战略，全力支持必康快速成长为行业的领军企业。
此前，必康制药曾先后获得红杉资本、光大控股、建银国际、新加坡大华、美国 SIG 等国际资本的投资，累计金额达 1.4 亿美元。
单伟建表示，必康是中国医药领域的重要企业，公司管理先进，产品线丰富，营销体系独特，业绩增长迅速，未来深具发展潜力。此次投资主要用于支持必康收购其它的制药企业，以及建设新的医药生产、研发、教育基地。
必康制药成立于 1 997 年，目前为必康控股通过必康国际全资控股的外商独资企业，是集原料药、中成药、化学药品、生物制剂、疫苗研发、生产和营销于一体的现代化大型医药企业集团。 2010 年度，必康制药在中国医药百强企业中排名第 45 位， 2011 年被国家药监局南方医药经济研究所评为 “中国最具成长扩张力公司”。
必康制药创始人李宗松表示，太盟投资集团以及单伟建先生是非常值得尊敬和信赖的合作伙伴，不但对必康制药的现状和未来战略有着深刻的认识和高度的认同，而且能够站在企业可持续发展的角度提供出色的建议。这种战略性资本的投资理念与企业高度吻合，加之专业化的管理，既能帮助必康制药巩固在企业经营和营销上已有的核心竞争力，还将提升其在资本市场的视野、形象和地位，推动必康更快更好的发展。
必康核心生产基地位于中药材资源丰富、环境清洁的陕西省商洛市山阳县，占地 110 亩，有着亚洲最大的单体 GMP 标准车间，净化面积 32500 平方米。拥有片剂、胶囊剂、软胶囊剂、颗粒剂、软膏剂、口服液、糖浆剂、大容量注射剂、小容量注射剂等 15 条生产线，年生产能力达 60 亿元以上；中药提取车间 5000 平方米，年提取能力达 8000 吨。生产的药品包括小儿化痰止咳颗粒、风痛宁片、枸橼酸铁铵维 B1 糖浆 II 、复方丹参片、五酯软胶囊等。
近年，必康并购整合能力突显，先后控股了武汉五景药业、江苏康宝制药、成都长青制药等多家制药企业，并参股河南开封制药集团等医药企业，开始了整合国内医药工商企业、建设覆盖城乡医药市场营销网络的战略布局，并由此拥有了中西药十多个系列、 1000 余种规格产品，其中进入国家基本用药和医保目录的品种有 300 多种。
必康于 2011 年在江苏徐州投资建立“新沂必康新医药产业综合体”。项目占地 1600 余亩，囊括了具备完善制药工业生产体系的制药园区、包装印刷车间、办公科研中心、后勤保障中心、商学院及技工学校等等。这一超大型医药产业综合体模式在国内尚属首家。
( 联系人 : 汪涛 wt@sxbicon.com)
Bicon Pharmaceutical Announces $250M Investment by PAG Asia Capital
(BEIJING, February 27) Shaanxi Bicon Pharmaceutical Company
Limited (“Bicon Pharmaceutical”) announces today that PAG Asia Capital (“PAG”)
has become the largest investor for its parent company Bicon Pharmaceutical
Holdings Limited (“Bicon”), with an investment of US$250 million (approximately
RMB1.6 billion). In connection with this investment, Bicon has also reorganized its Board of Directors.
Shan, Weijian, Chairman and CEO of PAG, has been appointed Chairman of the
Board. The eight-member Board consists of representatives of other institutional
investors such asSequoia, China Everbright Holdings, SIG, in addition to PAG,
and three members of the senior management including Li, Zongsong, Founder, Xiang, Xingfu, CEO, and Wang Chengjie, CFO.
“With our resources, capabilities and experiences, PAG will do everything in
its power to help the development of Bicon Pharmaceutical. Under the leadership
of the new board, the corporate governance and professional management of Bicon
will be further enhanced in accordance with international best practices,” Shan says.
Bicon is a leading player in China’s pharmaceutical industry. With an
experienced management, diversified product portfolio and unique sales and
distribution model, the company has achieved rapid growth and is well positioned
to continue its expansion. PAG’s investment will be primarily used for acquisitions and funding a new complex for both R&D and manufacturing.
Li, Zongsong, founder of Bicon Pharmaceutical, considers PAG a highly
respected and trusted partner. “PAG shares our vision and is expected to bring
its resources and operational capabilities to help us build our core competence
and strengthen our industry leadership position, in addition to bringing in word-class corporate governance.
Founded in 1997, Bicon Pharmaceutical is a wholly foreign-owned company.
Bicon Pharmaceutical is a leading pharmaceutical group with production, R&D,
and sales and distribution of Active Pharmaceutical Ingredients (API), modern
Chinese medicines, generic drugs, bio-pharmaceuticals and vaccines. In 2010,
Bicon Pharmaceutical ranked the 45th among the National Top 100
Pharmaceutical Enterprises in China. In 2011, it was accredited by Southern
Medicine Economic Institute of State Food and Drug Administration (SFDA) as the “Company with the Greatest Growth and Expansion Potential”.
Additional information about Bicon:
The main production base of Bicon Pharmaceutical is located in Shanyang
county in Shaanxi Province, where is known for its clean environment and
plentiful traditional Chinese medicinal resources. The production base covers an
area of 7.33 hectares and has the largest monomer workshop in Asia up to Good
Manufacturing Practice (GMP) standard, with a sterilization space of 32,500
square meters and 15 production lines of tablets, capsules, granules, ointment,
oral solution, syrup, injectibles. In addition, it has a herbal medicine
extraction workshop of 5,000 square meters with an annual extraction capacity of 8,000 tonnes.
Bicon’s products include Xiao’er Huatan Zhike Granule (Chinese medicine for
pediatric coughing), Fengtongning Tablet (Chinese medicine for arthritis),
Ammonium Ferric Citrate and Vitamin B1 Syrup, Fufang Danshen Tablet (Chinese
medicine for cardiovascular disorders), and Wuzhi Soft Capsule (Chinese medicine for hepatitis and liver protection).
In recent years, Bicon Pharmaceutical has acquired and integrated a number of
pharmaceutical companies in China, including Wuhan Wujing Pharmaceutical Co.,
Ltd., Jiangsu Kangbao Pharmaceutical Co., Ltd., and Chengdu Changqing
Pharmaceutical Co., Ltd. It has also made a strategic investment in Kaifeng
Pharmaceutical (Group) Co., Ltd. Through these acquisitions and investments,
Bicon now possesses a portfolio of over 1,000 products of traditional Chinese
and western drugs, covering over 10 treatment areas, of which over 300 products
are included in the National Reimbursement Drug List and the Essential Drug List.
In 2011, Bicon started the construction of “Bicon Integrated Pharmaceutical
Complex” in Xinyi county of Xuzhou city in Jiangsu Province. With a planned area
of more than 106 hectares, the complex will comprise of a pharmaceutical
production park equipped with advanced production systems, a packaging and
printing plant, an R&D and office center, a logistics and facility center
and a technical institute. This will be the first integrated pharmaceutical complex of such scale in China.
【